An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 243 participants.
Also called NCT02633293
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 243 participants
- Sponsor
- Registry
-
NCT02633293
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Terminated
Technical summary
Registry record NCT02633293. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-15 (actual); primary completion 2021-08-01 (actual). Results posted on 2022-12-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Condition
- Combined Pulmonary Fibrosis and Emphysema
- Intervention (Drug)
- Inhaled Treprostinil
- Lead sponsor
- United Therapeutics
Record details
- Record id
cardio:ct-nct02633293- Content hash
aa4ec330ea636131ba579e02e8242be42bd58fe0ebd73ddf81a7d249e30bc7d0